ABT - Abbott Laboratories
| Previous Close | 67.590 |
| Open | 67.740 |
| Bid | 68.130 x 800 |
| Ask | 68.140 x 1000 |
| Day's Range | 67.350 - 68.370 |
| 52 Week Range | 53.610 - 74.150 |
| Volume | 1,716,255 |
| Avg. Volume | 5,638,382 |
| Market Cap | 119.899B |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | 137.24 |
| EPS (TTM) | 0.498 |
| Earnings Date | Jan 22, 2019 - Jan 28, 2019 |
| Forward Dividend & Yield | 1.12 (1.66%) |
| Ex-Dividend Date | 2018-10-12 |
| 1y Target Est | 78.94 |
Markit•2 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABT
- Market Realist•3 days ago
Thermo Fisher: Analysts’ Estimates and Recommendations
Wall Street analysts expect Thermo Fisher Scientific’s (TMO) third-quarter revenues to increase ~11.5% to $5.7 billion—compared to its revenues of $5.1 million during the third quarter of 2017. The adjusted EPS is estimated to be $2.55 for the third quarter—compared to the adjusted EPS of $2.31 in the third quarter of 2017.
Market Realist•3 days agoGauging Analysts’ Views for NovoCure Stock
Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.
Market Realist•3 days agoNovoCure’s Operational Performance in Q3 2018: What to Expect
NovoCure’s (NVCR) gross income is expected to rise 28.22% to $44.82 million in the third quarter of 2018. Its gross margin is expected to contract from 69.76% in the third quarter of fiscal 2017 to 68.7% in the third quarter of fiscal 2018. NovoCure’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 67.97% and 72.72%, respectively.
- PR Newswire•3 days ago
Abbott's HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant
ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ -- Abbott (ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives. More than 5.7 million Americans suffer from heart failure, and there are approximately 915,000 new patients diagnosed with the disease annually.
Market Realist•3 days ago56% of Analysts Give ZBH a ‘Buy’ Rating before Its Q3 Earnings
On October 17, Zimmer Biomet Holdings (ZBH) stock closed at $128.32, an ~23.0% increase from its 52-week low of $104.28 on April 6. On October 16, Zimmer Biomet’s stock price recorded ~3.38% growth to reach $127.68 from its closing price of $123.50 on October 15. On September 21, Zimmer Biomet hit its 52-week high of $134.55. Segment revenue trends
- Investing.com•4 days ago
Abbott Labs Falls 3%
Investing.com - Abbott Labs (NYSE:ABT) fell by 3.10% to trade at $68.05 by 13:19 (17:19 GMT) on Thursday on the NYSE exchange.
Market Realist•4 days agoZimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings
Zimmer Biomet Holdings (ZBH) plans to release its third-quarter earnings on October 26. Wall Street analysts expect ZBH to generate revenues of $1.8 billion in the third quarter.
GuruFocus.com•4 days agoAbbott Labs Declines on 3rd-Quarter Earnings
The U.S. health care company Abbott Laboratories (ABT) reported strong third-quarter results before the opening bell on Wednesday, though shares declined 1.01% to $70.23. On a GAAP basis, earnings per share were 31 cents. Warning! GuruFocus has detected 7 Warning Sign with ABT.
- Investopedia•4 days ago
4 MedTech Names to Buy on 'Strong Fundamentals'
In a note to clients on Tuesday, Barclays analyst Kristen Stewart highlighted the investment bank's favorite picks in the red-hot sector. Barclays is particularly bullish on shares of Abbot Labs, due to the company's promising product pipeline and "favorable mix of businesses." Stewart's 12-month price forecast on shares of the Chicago-based company at $80 imply a near 16% upside from current levels.
Market Realist•4 days agoWhat Analysts Expect for Boston Scientific Stock
Of the total 25 analysts covering Boston Scientific (BSX) in October 2018, 22 analysts have given Boston Scientific a “buy” or higher rating, and three analysts have given Boston Scientific a “hold” rating. The mean rating for Boston Scientific is 1.52 with a target price of $41.57, which implies an upside potential of 9.4% over Boston Scientific’s closing price of $38.0 on October 17, 2018.
Market Realist•4 days agoWhat Will BSX’s Q3 Operational Performance Look Like?
Boston Scientific’s (BSX) gross income is expected to increase by 9.26% from $1.58 billion in the third quarter of fiscal 2017 to $1.73 billion in the third quarter of fiscal 2018. Its gross margin is expected to expand from 71.33% for the third quarter of fiscal 2017 to 71.95% for the third quarter of fiscal 2018.
Markit•4 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABT
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of ABT earnings conference call or presentation 17-Oct-18 1:00pm GMT
Q3 2018 Abbott Laboratories Earnings Call
- TheStreet.com•5 days ago
Dow Slips for Fifth Day in Seven, Led Lower by IBM, Home Depot
The Dow trades lower as a slump in shares of IBM prevents the index from a significant move into positive territory.
InvestorPlace•5 days ago5 Top Stock Trades for Thursday
For the most part, the stock market hung onto most of its gains following Tuesday’s monstrous move. As we get into earnings seasons though, investors will have to fight against both market-wide volatility and giant moves in individual stocks.10 Marijuana Stocks for the Canadian 'Pot Rush'
- Zacks•5 days ago
Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
Motley Fool•5 days agoAbbott Laboratories (ABT) Q3 2018 Earnings Conference Call Transcript
ABT earnings call for the period ending September 30, 2018.
- PR Newswire•5 days ago
New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ -- For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. More than seven billion diagnostic tests are run in the U.S. each year to help physicians make accurate, timely decisions about a person's medical treatment.2 Point-of-care diagnostic tests, that can often provide results within minutes, are used globally as hospitals face increased pressures to address overcrowding in emergency rooms and longer wait times.
GuruFocus.com•5 days agoBarclays Takes Action on Health Care Stocks
The firm has initiated coverage of Abbott Labs, Boston Scientific, Medtronic, Stryker and others
- InvestorPlace•5 days ago
ABT Stock Dips Following Q3 Earnings Results
This is an increase over the company’s earnings per share of 66 cents during the same time last year. It also matches Wall Street’s earnings per share estimate for the quarter, but couldn’t keep ABT stock from falling today. During the third quarter of 2018, Abbott Laboratories reported net income of $563 million.
- Investing.com•5 days ago
Abbott Labs Earnings, Revenue beat in Q3
Investing.com - Abbott Labs (NYSE:ABT) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.
- Zacks•5 days ago
Q3 Earnings Stay (Mostly) Strong, Plus Housing Data
With new Housing Starts, Building Permits and Mortgage Application data, we continue to collect new Q3 earnings results, particularly from UAL, ABT and USB.
- Investing.com•5 days ago
Stocks- U.S. Futures Fall as Investors Look Ahead to Fed Minutes
Investing.com – U.S. futures pointed to a lower opening bell, as investors paused to digest earnings results and waited for the latest meeting minutes from the Federal Reserve.The S&P 500 futures fell 7 points or 0.27% to 2,810.25 as of 6:50 AM ET (10:50 GMT) while Dow futures were down 76 points, or 0.29%, to 25,706.0. Meanwhile tech heavy Nasdaq 100 futures decreased 19 points, or 0.26%, to 7,334.50. ...
